Abemaciclib NEW

$1.10 100kg

$3.30 25kg

$9.90 1kg

Min. Order1kg
Purity99%min
Cas No1231929-97-7
Supply Ability100kg
Update time2025-10-13

ZHENGZHOU JIUYI TIME NEW MATERIALS CO,.LTD

VIP1Y

China

Chemical Properties

Product Name	Abemaciclib
CAS No	1231929-97-7
EC-No
Min. Order	1kg
Purity	99%min
Supply Ability	100kg
Release date	2025/10/13

Abemaciclib

Modify Date: 2024-01-02 15:46:50

Abemaciclib structure	Common Name	Abemaciclib
	CAS Number	1231929-97-7	Molecular Weight	506.593
	Density	1.3±0.1 g/cm3	Boiling Point	689.3±65.0 °C at 760 mmHg
	Molecular Formula	C27H32F2N8	Melting Point	N/A
	MSDS	N/A	Flash Point	370.7±34.3 °C

Purity		Quantity		Budget		Inquiry

Use of Abemaciclib

Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.

Properties

Name	N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine
Synonym	More Synonyms

Description	Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.
Related Catalog	Research Areas >> Cancer
Target	Cdk4/cyclin D1:2 nM (IC50) CDK6/cyclinD1:10 nM (IC50) CDK9/cyclinT1:57 nM (IC50) CDK5/p35:287 nM (IC50) Cdk5/p25:355 nM (IC50) CDK2/cyclinE:504 nM (IC50) CDK7/Mat1/cyclinH1:3910 nM (IC50) CDK1/cyclinB1:1627 nM (IC50) PIM1:50 nM (IC50) PIM2:3400 nM (IC50) HIPK2:31 nM (IC50) DYRK2:61 nM (IC50) CK2:117 nM (IC50) GSK3b:192 nM (IC50) JNK3:389 nM (IC50) FLT3 (D835Y):403 nM (IC50) FLT3:3960 nM (IC50) DRAK1:659 nM (IC50)
In Vitro	Abemaciclib reduces cell viability with the IC50 values ranging from 0.5 μM to 0.7 μM, inhibits Akt and ERK signaling but not mTOR activation at head and neck squamous cell carcinoma (HNSCC) cells[1]. Abemaciclib shows inhibition on A375R1-4, M14R, and SH4R with EC50 values ranging from 0.3 to 0.6 μM; Abemaciclib inhibits the proliferation of the parental A375 and resistant A375RV1 and A375RV2 cells with similar potencies with IC50 values of 395, 260, and 463 nM, respectively[2]. Abemaciclib inhibits CDK4 and CDK6 with low nanomolar potency, inhibits Rb phosphorylation resulting in a G1 arrest and inhibition of proliferation, and its activity is specific for Rb-proficient cells[3].
In Vivo	Abemaciclib (45 mg/kg, p.o.) in combination with everolimus causes a cooperative antitumor effect in HNSCC xenograft tumor[1]. Abemaciclib (45 or 90 mg/kg, p.o.) shows significant tumor growth inhibition in an A375 xenograft model[2].
Cell Assay	Cells are seeded in a 96-well plate, allowed to adhere overnight, and treated with DMSO control (0.1% v/v) or the indicated compounds for 72 h. Cell viability and proliferation are determined using a Cell Counting Kit according to the manufacturer's instructions. The interaction between Abemaciclib and mTOR inhibitor is determined using CompuSyn. Combination index (CI) values of 1 indicates and additive drug interaction, whereas a CI of <1 is synergistic and a CI of >1 is antagonistic.
Animal Admin	Six-week-old BALB/c female nude mice are injected subcutaneously with OSC-19 (1×106) cells. When tumor sizes reach approximately 100 mm3, mice are randomized by tumor size and subjected to each treatment. At least 5 mice per treatment group are included. Each group of mice is dosed via daily oral gavage with vehicle, Abemaciclib (45 mg/kg/d or 90 mg/kg/d), Everolimus (5 mg/kg/d), or a combination of both. The Abemaciclib is dissolved in 1% HEC in 20 mM phosphate buffer (pH2.0). Tumor size and body weight are measured twice weekly. Tumor volumes are calculated using the following formula: V=(L×W2)/2. Mice are gavaged a final time on day 14 and sacrificed the following day. The tumors are removed for Western blot and immunohistochemistry.
References	[1]. Ku BM, et al. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma. Oncotarget.?2016 Mar 22;7(12):14803-13. [2]. Yadav V, et al. The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation. Mol Cancer Ther. 2014 Oct;13(10):2253-63. [3]. Gelbert LM, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs. 2014 Oct;32(5):825-37.

Density	1.3±0.1 g/cm3
Boiling Point	689.3±65.0 °C at 760 mmHg
Molecular Formula	C27H32F2N8
Molecular Weight	506.593
Flash Point	370.7±34.3 °C
Exact Mass	506.271790
PSA	75.00000
LogP	2.74
Vapour Pressure	0.0±2.2 mmHg at 25°C
Index of Refraction	1.656

Company Profile

Our company is a high-tech enterprise specializing in chemical raw materials such as electronic materials, optoelectronic materials, semiconductor materials, UV monomers, silane catalysts, cosmetic raw materials, etc.

We are committed to providing high-quality chemical products and comprehensive solutions to meet the diverse needs of the global market.

Our research and development team possesses profound professional knowledge and extensive industry experience, dedicated to developing cutting-edge chemical materials to drive technological progress and industrial development. Our production facilities are equipped with state-of-the-art technology and a stringent quality control system to ensure product consistency and reliability.

As a pioneer in the industry, we not only offer standardized products but also customize chemicals and services according to the specific needs of our customers. Our goal is to become a trusted partner for global customers through continuous technological innovation and superior customer service.

Our Company

Our Advantage

Quality control

Based on industry norms, customer requirements, and internal quality objectives, we establish clear quality standards. By monitoring the production process in real-time, we ensure that every step conforms to the predetermined quality standards.

Excellent quality is one of the cornerstones of our success. We welcome ordering samples for quality testing.

Technological innovation

Our technological innovation is reflected in the development of new materials that are at the leading edge of the industry. These materials not only possess higher performance and lower costs but also enable sustainable use within an environmentally friendly production process.

Competitiveness

Based on rich experience in material development and production, we have established a more scientific cost control system. By ensuring product quality, and through refined management and continuous process optimization, we offer more competitive prices.

Word of mouth

Adhering to the principle of customer first, customer first, and honest service, we have established long-term business relationships with customers and are deeply welcomed and trusted by them.

Rich experience

Our products have been exported to many countries, including Germany, Spain, the United Kingdom, the United States, Australia, the Middle East, Asia, and more. We have received highly positive feedback from our clients and have established long-term friendly cooperative relationships with them.